These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 3420569

  • 1. [Drug nephrotoxicity. A microcomputerized databank of renal involvement and responsible "nephrotox" drugs].
    Hamel JD, Biour M, Cheymol G.
    Therapie; 1988 May; 43(3):211-7. PubMed ID: 3420569
    [No Abstract] [Full Text] [Related]

  • 2. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD, Biour M, Cheymol G.
    Therapie; 1986 May; 41(5):327-9. PubMed ID: 3810519
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J.
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract] [Full Text] [Related]

  • 6. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M, Wagniart F, Jablonka J, Hamel JD, Weissenburger J, Cheymol G.
    Therapie; 1986 Mar; 41(5):383-4. PubMed ID: 3810530
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rhode Island physicians' recognition and reporting of adverse drug reactions.
    Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP, Faich GA.
    R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Overview of different logistical approaches to postmarketing surveillance.
    Strom BL.
    J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621
    [Abstract] [Full Text] [Related]

  • 16. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR, Sapatnekar SM.
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract] [Full Text] [Related]

  • 17. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M.
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [Abstract] [Full Text] [Related]

  • 18. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM.
    Circulation; 2005 Jan 25; 111(3):246-8. PubMed ID: 15668350
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.